Cosmax (A192820) Q2 2025 earnings summary
Event summary combining transcript, slides, and related documents.
Q2 2025 earnings summary
23 Jun, 2026Executive summary
Achieved record high revenue of KRW 623.6 bn (+13.1% YoY) and operating profit of KRW 60.8 bn (+30.2% YoY) in Q2 2025, driven by global expansion and regional strategies.
Revenue for H1 2025 was KRW 1,212.1 billion, with operating income of KRW 112.2 billion and net profit of KRW 32.5 billion.
Net profit declined 38.1% YoY to KRW 21.8 bn in Q2 due to increased non-operating expenses, including interest and FX losses.
The company operates as a global leader in cosmetics ODM, supplying over 3,300 brands worldwide, with a strong focus on R&D and global production infrastructure.
The company maintains a robust ESG profile, with significant achievements in sustainability and environmental certifications.
Financial highlights
Consolidated revenue for H1 2025: KRW 1,212.1 billion; operating income: KRW 112.2 billion; net profit: KRW 32.5 billion.
Q2 2025 revenue rose 13.1% YoY to KRW 623.6 bn; operating profit up 30.2% YoY to KRW 60.8 bn.
Gross profit increased slightly by 0.7% YoY to KRW 112.9 bn in Q2; SG&A expenses fell 20.3% YoY.
Basic EPS for H1 2025: KRW 2,561.
Cash and cash equivalents at period end: KRW 219.0 billion.
Outlook and guidance
US revenue expected to recover in 2H 2025 by focusing on high-growth categories like suncare and body care.
Continued emphasis on global market expansion, tailored regional strategies, and investment in R&D and digital transformation.
Latest events from Cosmax
- H1 2024 revenue reached ₩1,078.3B with net income of ₩54.9B, led by Korea and Southeast Asia growth.A192820
Q2 202423 Jun 2026 - Q1 2025 revenue and operating profit grew, but net profit fell due to one-off and non-operating losses.A192820
Q1 202523 Jun 2026 - Revenue up 1.0% YoY, but profit declined on one-off costs; R&D and ESG efforts remain strong.A192820
Q3 202523 Jun 2026 - Q1 2026 revenue up 15.9% YoY and net profit up 312.1%, driven by Korea and China growth.A192820
Q1 202631 May 2026 - Strong revenue and profit growth in 4Q 2025, led by health supplement and holding segments.A192820
Q4 20258 Mar 2026 - Korea and Southeast Asia drove robust profit growth, offsetting China and US weakness.A192820
Q3 202420 Feb 2026 - Record Q4 profit growth driven by Korea and Southeast Asia, with net profit turning positive.A192820
Q4 202420 Feb 2026